Metabolic Bone Disease and Genetic Research Unit, Department of Osteoporosis and Bone Diseases, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Metabolic Bone Disease and Genetic Research Unit, Department of Osteoporosis and Bone Diseases, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
J Clin Densitom. 2019 Apr-Jun;22(2):179-184. doi: 10.1016/j.jocd.2018.08.005. Epub 2018 Aug 22.
Fibroblast growth factor 21 (FGF21) is a member of the endocrine FGF subfamily and an important metabolic regulator that has multiple beneficial effects on glucose homeostasis and lipid metabolism. However, it was unclear whether FGF21 would induce bone defects in humans. This study evaluated the associations of FGF21 levels, bone mineral density (BMD), osteoporotic fracture, and bone turnover marks (BTMs) in postmenopausal women. A total of 1342 postmenopausal Chinese Han women (511 cases of fragility fracture in the case group and 831 cases in nonfragility fracture group) were enrolled. Serum FGF21 concentration was measured by ELISA (Quantikine), serum calcium (Ca), phosphate (P), alkaline phosphatase, 25-hydroxyvitamin D, parathyroid hormone, β-crosslinked C-telopeptide of type l collagen, were measured using an automated Roche electro-chemiluminescence system. BMD was measured using dual-energy X-ray absorptiometry. The association with age, BMD, 25-hydroxyvitamin D, parathyroid hormone, β-crosslinked C-telopeptide of type l collagen, and FGF21 levels were also evaluated in postmenopausal women. In nonfracture group and fragility fracture group, postmenopausal women's FGF21 level was 226.57pg/mL (149.11-354.43 pg/mL) and 219.43pg/mL (147.21-323.74 pg/mL), respectively. There is no significant difference in serum FGF21 levels between the fragility fracture group and the nonfracture group (p = 0.160). There was a significant statistical difference in BMD between the fragility fracture group and the nonfracture group (p = 0.000). In multiple linear regression analysis, FGF21 levels were significantly positive associated with lumbar BMD in postmenopausal women (L1-4, p = 0.007), independent of other factors, especially in fragility fracture group (L1-4, p = 0.001). In addition, a significant positive association was also observed between serum FGF21 levels and age in postmenopausal women (p < 0.05). We reveal a positive correlation between serum FGF21 concentrations with lumbar BMD in Chinese Han postmenopausal women. No significant correlations are present between serum FGF21 and bone turnover marks or serum FGF21 and fragility fracture in our study.
成纤维细胞生长因子 21（FGF21）是内分泌 FGF 亚家族的成员，是一种重要的代谢调节剂，对葡萄糖稳态和脂代谢有多种有益作用。然而，FGF21 是否会在人类中引起骨缺陷尚不清楚。本研究评估了绝经后妇女的 FGF21 水平、骨密度（BMD）、骨质疏松性骨折和骨转换标志物（BTMs）之间的相关性。共纳入 1342 例绝经后汉族女性（脆性骨折组 511 例，非脆性骨折组 831 例）。采用酶联免疫吸附试验（ELISA）（Quantikine）检测血清 FGF21 浓度，采用罗氏电化学发光系统自动检测血清钙（Ca）、磷（P）、碱性磷酸酶、25-羟维生素 D、甲状旁腺激素、I 型胶原交联 C 端肽-β。采用双能 X 线吸收法测量 BMD。还评估了年龄、BMD、25-羟维生素 D、甲状旁腺激素、I 型胶原交联 C 端肽-β与绝经后妇女 FGF21 水平的相关性。在非骨折组和脆性骨折组中，绝经后妇女的 FGF21 水平分别为 226.57pg/mL（149.11-354.43pg/mL）和 219.43pg/mL（147.21-323.74pg/mL）。脆性骨折组与非骨折组血清 FGF21 水平无显著性差异（p=0.160）。脆性骨折组与非骨折组的 BMD 有显著统计学差异（p=0.000）。在多元线性回归分析中，FGF21 水平与绝经后妇女腰椎 BMD 呈显著正相关（L1-4，p=0.007），独立于其他因素，尤其是脆性骨折组（L1-4，p=0.001）。此外，还观察到血清 FGF21 水平与绝经后妇女年龄之间存在显著正相关（p<0.05）。本研究揭示了汉族绝经后妇女血清 FGF21 浓度与腰椎 BMD 之间存在正相关。在我们的研究中，血清 FGF21 与骨转换标志物之间没有显著相关性，血清 FGF21 与脆性骨折之间也没有显著相关性。
